High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: An international extranodal lymphoma study group and intergruppo Italiano linfomi study

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 823-832

  Mian, Michael ^a,b,l   Gaidano, Gianluca ^c   Conconi, Annarita ^c   Tsang, Richard ^d   Gospodarowicz, Mary K ^d   Rambaldi, Alessandro ^e   Rossi, Andrea ^e   Oldani, Elena ^e   Federico, Massimo ^f   Luminari, Stefano ^f   Bellei, Monica ^f   Pogliani, Enrico M ^g   Rossini, Fausto ^g   Cabrera, Maria Elena ^h   Martelli, Maurizio ⁱ   Lopez Guillermo, Armando ^j   Busetto, Mario ^j   Cavalli, Franco ^k   Zucca, Emanuele ^k   Cortelazzo, Sergio ^a  

^a Azienda Ospedaliera S Maurizio   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e OSPEDALI RIUNITI   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

^h HOSPITAL DEL SALVADOR   (Chile)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j HOSPITAL CLÍNIC   (Spain)

^k REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^l CENTRAL HOSPITAL OF BOLZANO   (Italy)

more..

Author keywords

DLBCL; lymphoma; thyroid; treatment

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DYSPHAGIA; DYSPNEA; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HASHIMOTO DISEASE; HOARSENESS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIMARY THYROID DIFFUSE LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SARCOMA; THYROID CANCER; THYROIDECTOMY; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 79955067625     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.555888     Document Type: Article

References (65)

1. Green LD, Mack L, Pasieka JL. Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol 2006;94:725-736. (Pubitemid 44902073)
2. Pedersen RK, Pedersen NT. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology 1996;28:25-32. (Pubitemid 26040138)
3. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260.
4. Aozasa K, Inoue A, Tajima K, Miyauchi A, Matsuzuka F, Kuma K. Malignant lymphomas of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors. Cancer 1986;58:100-104. (Pubitemid 16093110)
5. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1-12. (Pubitemid 39625035)
6. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164. (Pubitemid 46606184)
7. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, FerreriAJ, Ponzoni M, Devizzi L, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495. (Pubitemid 36857603)
8. Singer JA. Primary lymphoma of the thyroid. Am Surg 1998;64:334-337. (Pubitemid 28158228)
9. Mack LA, Pasieka JL. An evidence-based approach to the treatment of thyroid lymphoma. World J Surg 2007;31:978-986. (Pubitemid 46716757)
10. Doria R, Jekel JF, Cooper DL. Thyroid lymphoma. The case for combined modality therapy. Cancer 1994;73:200-206. (Pubitemid 24012745)
11. Burton GV, Atwater S, Borowitz MJ, Huang AT. Extranodal head and neck lymphoma. Prognosis and patterns of recurrence. Arch Otolaryngol Head Neck Surg 1990;116:69-73. (Pubitemid 20045477)
12. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993;3:93-99. (Pubitemid 23199730)
13. Friedberg MH, Coburn MC, Monchik JM. Role of surgery in stage IE non-Hodgkin's lymphoma of the thyroid. Surgery 1994;116:1061-1066; discussion 1066-1067.
14. Ha CS, Shadle KM, Medeiros LJ, Wilder RB, Hess MA, Cabanillas F, Cox JD. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer 2001;91:629-635. (Pubitemid 32173285)
15. DiBiase SJ, Grigsby PW, Guo C, Lin HS, Wasserman TH. Outcome analysis for stage IE and IIE thyroid lymphoma. Am J Clin Oncol 2004;27:178-184. (Pubitemid 38451481)
16. Niitsu N, Okamoto M, Nakamura N, Nakamine H, Bessho M, Hirano M. Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma. Ann Oncol 2007;18:1203-1028.
17. Tsang RW, Gospodarowicz MK, Sutcliffe SB, Sturgeon JF, Panzarella T, Patterson BJ. Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group. Int J Radiat Oncol Biol Phys 1993;27:599-604. (Pubitemid 23331127)
18. Skacel M, Ross CW, Hsi ED. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma. Histopathology 2000;37:10-18. (Pubitemid 30496730)
19. Belal AA, Allam A, Kandil A, El Husseiny G, Khafaga Y, Al Rajhi N, Ahmed G, Gray A, Ajarim D, Schultz H, et al. Primary thyroid lymphoma: a retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma. Am J Clin Oncol 2001;24:299-305. (Pubitemid 32520640)
20. Kuper-Hommel MJ, Snijder S, Jansen-Heijnen ML, Vreug-denhil A, Noordijk EM, Kluin-Nelemans HC, Coebergh JW, van Krieken JH. Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. Clin Lymphoma Myeloma 2005;6:240-247.
21. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000;24:623-639. (Pubitemid 30253500)
22. Miller T, LeBlanc M, Spier C, Chase E, Fischer R, Group SO. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial Blood 2001;98(Suppl. 1): 724a-725a. Abstract 3024.
23. Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SE, Sutcliffe S, Connors JM. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197-204. (Pubitemid 34032612)
24. Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJM, Pinotti G, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol 2002;118:218-228. (Pubitemid 34779540)
25. Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999;10:1433-1440. (Pubitemid 30017052)
26. Jaffe E, Harris N, Stein H, Vardiman J. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon: World Health Organization classification of tumours; 2001.
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP, Zubrod. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655. (Pubitemid 13149996)
28. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
29. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-1493.
30. Martinelli G, Ferrucci PF, Mingrone W, Cocorocchio E, Conconi A, Peccatori FA, De Luzio K, Santoro P, Mazzetta C, Zucca E, et al. ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:801-806. (Pubitemid 36410985)
31. Abate G, Comella P, Di Pietro N, Ganzina F, Pergola M, Silvestro P, Basso A, Salvatore M, Zarrilli D. Epirubicin in combination chemotherapy in the treatment of advanced stage non-Hodgkin's lymphomas. Tumori 1987;73:43-47. (Pubitemid 17034486)
32. Merli F, Bertini M, Sacchi S, Liberati AM, Malorgio F, Vitolo U, Stelitano C, Freilone R, Polimeno G, Galliano M, et al. A pilot study with an oral chemotherapy regimen (CIEP) in the treatment of diffuse large cell lymphoma (DLCL) in elderly patients: an interim report from Italian Lymphoma Intergroup (ILI). Ann Oncol 2002;13(Suppl. 2): Abstract 554.
33. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994;5:895-900.
34. Armitage JO. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. Ann Oncol 1991;2(Suppl. 1): 37-41.
35. Portlock CS, Rosenberg SA. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. Cancer 1976;37:1275-1282.
36. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
37. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
38. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
39. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176. (Pubitemid 24173930)
40. Abdul-Rahman ZH, Gogas HJ, Tooze JA, Anderson B, Mansi J, Sacks NP, Finlayson CJ. T-cell lymphoma in Hashimoto's thyroiditis. Histopathology 1996;29:455-459. (Pubitemid 26384179)
41. Mizukami Y, Michigishi T, Nonomura A, Nakamura S, Hashimoto T, Katsuda S, Otake S, Matsubara F. Primary lymphoma of the thyroid: a clinical, histological and immunohistochemical study of 20 cases. Histopathology 1990;17: 201-209. (Pubitemid 20275961)
42. Sasai K, Yamabe H, Haga H, Tsutsui K, Dodo Y, Ishigaki T, Shibamoto Y, Abe M. Non-Hodgkin's lymphoma of the thyroid. A clinical study of twenty-two cases. Acta Oncol 1996;35:457-462. (Pubitemid 26233045)
43. Yamaguchi M, Ohno T, Kita K. Gamma/delta T-cell lymphoma of the thyroid gland. N Engl J Med 1997;336: 1391-1392. (Pubitemid 27208630)
44. Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1, 408 cases. Surgery 2009;146:1105-1115.
45. Hwang YC, Kim TY, Kim WB, Shong YK, Yi KH, Shong M, Jo YS, Kim WS, Chung JH. Clinical characteristics of primary thyroid lymphoma in Koreans. Endocr J 2009;56:399-405.
46. Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, Berger F, Ducottet X, Martin C, Salles G, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002;87:105-111. (Pubitemid 34084678)
47. Anscombe AM, Wright DH. Primary malignant lymphoma of the thyroid - a tumour of mucosa-associated lymphoid tissue: review of seventy-six cases. Histopathology 1985;9:81-97. (Pubitemid 15170642)
48. Moshynska OV, Saxena A. Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma. J Clin Pathol 2008;61:438-444. (Pubitemid 351518224)
49. Saxena A, Alport EC, Moshynska O, Kanthan R, Boctor MA. Clonal B cell populations in a minority of patients with Hashimoto's thyroiditis. J Clin Pathol 2004;57:1258-1263. (Pubitemid 39611509)
50. Matsubayashi S, Tamai H, Morita T, Fukata S, Matsuzuka F, Suzuki T, Kuma K, Nagataki S, Volpe R. Hashimoto's thyroiditis manifesting monoclonal lymphocytic infiltration. Clin Exp Immunol 1990;79:170-174. (Pubitemid 20058451)
51. Wacker HH, Tiemann M, Menke MA, Back A, Parwaresch RM. [Intensification of sensitivity of monoclonality determi-nation of B-cells in autoimmune thyroiditis and low malig-nancy B-NHL of the MALT type using temperature gradient gel electrophoresis (TGGE)]. Verh Dtsch Ges Pathol 1994; 78:208-213.
52. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol 1999;26:316-323. (Pubitemid 29272899)
53. Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, Atasoy BM, Igdem S, Ozsahin M, Ozyar E. Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study. Ann Oncol 2011;22:156-164.
54. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26. (Pubitemid 28304493)
55. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-3038. (Pubitemid 41103714)
56. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-1205. (Pubitemid 40397261)
57. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787-792. (Pubitemid 350002878)
58. Barosi G, Carella A, Lazzarino M, et al. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006;91:96-103. (Pubitemid 43235392)
59. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221-236.
60. Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 2010 Jun 15. [Epub ahead of print].
61. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010;51:797-801.
62. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma 2006;47:1683-1685. (Pubitemid 44364040)
63. Gutiérrez-Garcia G, Colomo L, Villamor N, Arenillas L, Martinez A, Cardesa T, Garcia-Herrera A, Setoain X, Rodriguez S, Ghita G, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010;51:1225-1232.
64. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
65. Foppiani L, Secondo V, Arlandini A, Quilici P, Cabria M, Del Monte P. Thyroid lymphoma: a rare tumor requiring combined management. Hormones (Athens) 2009;8:214-218.